Basic Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2015; 21(20): 6157-6166
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6157
Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model
Linda S Gutierrez, Jun Ling, Derek Nye, Konstantina Papathomas, Catherine Dickinson
Linda S Gutierrez, Derek Nye, Konstantina Papathomas, Catherine Dickinson, Department of Biology and Health Sciences, Wilkes University, Wilkes-Barre, PA 18766, United States
Jun Ling, Department of Basic Sciences, The Commonwealth Medical College, Scranton, PA 18501, United States
Author contributions: Gutierrez LS designed the study, performed some experiments, wrote the manuscript and provided financial support for this work; Ling J performed some experiments, edited the manuscript and provided financial support for this work; Nye D, Papathomas K and Dickinson C performed most of the experiments.
Supported by National Institutes of Health (AREA), No. R15 DK067901-02; the Howard Hughes Medical Institute, No. 52006328; Wilkes Mentoring funds and institutional funds from Wilkes University and TCMC.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Linda S Gutierrez, MD, Department of Biology and Health Sciences, Wilkes University, 230 Cohen Science Center, 84 West South Street, Wilkes-Barre, PA 18766, United States. linda.gutierrez@wilkes.edu
Telephone: +1-570-4084636 Fax: +1-570-4087862
Received: July 25, 2014
Peer-review started: July 26, 2014
First decision: September 27, 2014
Revised: November 10, 2014
Accepted: December 20, 2014
Article in press: December 22, 2014
Published online: May 28, 2015
Processing time: 309 Days and 2.8 Hours
Core Tip

Core tip: Inflammatory bowel disease is still incurable and a major burden in the patient’s life and health care system. The discovery of new and safe therapeutic alternatives is urgently needed. This study tested the efficacy of a new thrombospondin- derived peptide, ABT-898 in a murine model of colitis. Our results indicate that this peptide was able to ameliorate inflammation and angiogenesis. In addition, mice treated with ABT-898 showed significant decrease of plasmatic Interleukin-6 and lesser activation of signal transducer and activator of transcription 3 in colitic lesions. These findings suggest that ABT-898 may indeed be an alternative treatment for inflammatory bowel disease.